Compare GE Vernova Inc (GEV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

GE Vernova IncTrade

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

GE Vernova Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? GE Vernova Inc trades at $1,026.01 (market cap $269.50B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: GE Vernova Inc is far larger — about 2× Vertex Pharmaceuticals Incorporated's market cap, and GE Vernova Inc pays a 0.2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

	GEV	VRTX
Market Cap	$269.50B	$134.25B
Sector	Technology	Health
52-Week High	$1.17K	$529.65
52-Week Low	$547.96	$376.62
Enterprise Value	$259.17B	$128.37B
Dividend Yield	0.2%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GEV

GE Vernova benefits from AI-driven power and grid bottlenecks but faces high expectations at 28x 2028 earnings.Seeking Alpha · 7 hours agoNeutral Invesco S&P 500 Equal Weight Energy ETF rated Buy for balanced energy sector exposure amid oil market shifts.Seeking Alpha · 1 day agoBullish View details →

VRTX

View details →

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.